These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 2036943

  • 1. [The effect of molsidomine on portal and cardiac hemodynamics in liver cirrhosis].
    Hüppe D, Jäger D, Tromm A, Tunn S, Barmeyer J, May B.
    Dtsch Med Wochenschr; 1991 May 31; 116(22):841-5. PubMed ID: 2036943
    [Abstract] [Full Text] [Related]

  • 2. [The long-term effect of molsidomine on frequency of hemorrhage, portal and cardiac hemodynamics in patients with liver cirrhosis--a pilot study].
    Hüppe D, Jäger D, Tromm A, Barmeyer J, May B.
    Leber Magen Darm; 1993 May 31; 23(3):114-8, 121-2. PubMed ID: 8326815
    [Abstract] [Full Text] [Related]

  • 3. Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis.
    García-Pagán JC, Escorsell A, Feu F, Bandi JC, Moitinho E, Casado M, Bosch J, Rodés J.
    J Hepatol; 1996 Apr 31; 24(4):430-5. PubMed ID: 8738729
    [Abstract] [Full Text] [Related]

  • 4. Nicardipine infusion improved hepatic function but failed to reduce hepatic venous pressure gradient in patients with cirrhosis.
    Iwao T, Toyonaga A, Ikegami M, Sugawara H, Sumino M, Takagi K, Oho K, Sakaki M, Ohkubo K, Inoue R.
    Am J Gastroenterol; 1992 Mar 31; 87(3):326-31. PubMed ID: 1539567
    [Abstract] [Full Text] [Related]

  • 5. Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis.
    Ruiz del Arbol L, García-Pagán JC, Feu F, Pizcueta MP, Bosch J, Rodés J.
    J Hepatol; 1991 Sep 31; 13(2):179-86. PubMed ID: 1744422
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK, Bandyopadhyay K, Das TK, Das D, Biswas PK, Majumdar D, Mandal SK, Ray S, Dasgupta S.
    Am J Gastroenterol; 2003 Jun 31; 98(6):1371-6. PubMed ID: 12818283
    [Abstract] [Full Text] [Related]

  • 8. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
    Bosch J, Kravetz D, Rodes J.
    Gastroenterology; 1981 Mar 31; 80(3):518-25. PubMed ID: 6108897
    [Abstract] [Full Text] [Related]

  • 9. Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis.
    Combis JM, Vinel JP, Badia P, Barange K, Payen JL, Combis F, Desmorat H, Pascal JP.
    Br J Clin Pharmacol; 1996 May 31; 41(5):409-13. PubMed ID: 8735682
    [Abstract] [Full Text] [Related]

  • 10. [Correlation between hemodynamic parameters of the portal circulation in cirrhotic patients].
    Bretagne JF, Bourguet P, Morisot D, Duvauferrier R, Darnault P, Gastard J.
    Gastroenterol Clin Biol; 1985 Oct 31; 9(10):674-8. PubMed ID: 4065489
    [Abstract] [Full Text] [Related]

  • 11. Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis.
    Desmorat H, Vinel JP, Lahlou O, Pipy B, Badia P, Cales P, Combis JM, Souqual MC, Pascal JP.
    Hepatology; 1991 Jun 31; 13(6):1181-4. PubMed ID: 2050332
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis.
    Vinel JP, Monnin JL, Combis JM, Calés P, Desmorat H, Pascal JP.
    Hepatology; 1990 Feb 31; 11(2):239-42. PubMed ID: 2307402
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Portohepatic pressures, hepatic function, and blood gases in the combination of nitroglycerin and vasopressin: search for additive effects in cirrhotic portal hypertension.
    Iwao T, Toyonaga A, Ikegami M, Sumino M, Oho K, Sakaki M, Nishizono M, Tanikawa K.
    Am J Gastroenterol; 1992 Jun 31; 87(6):719-24. PubMed ID: 1590307
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
    Braillon A, Calès P, Lebrec D.
    Int J Clin Pharmacol Res; 1985 Jun 31; 5(4):223-8. PubMed ID: 4055165
    [Abstract] [Full Text] [Related]

  • 17. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.
    Ikegami M, Toyonaga A, Tanikawa K.
    Am J Gastroenterol; 1992 Sep 31; 87(9):1160-4. PubMed ID: 1519573
    [Abstract] [Full Text] [Related]

  • 18. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J.
    Gastroenterology; 2009 May 31; 136(5):1651-8. PubMed ID: 19208350
    [Abstract] [Full Text] [Related]

  • 19. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW, Kalk JF, Klein CP.
    Hepatology; 1999 Feb 31; 29(2):334-9. PubMed ID: 9918907
    [Abstract] [Full Text] [Related]

  • 20. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation.
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):433-9. PubMed ID: 16128681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.